Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201207036 Principal Investigator: Govindan, Ramaswamy
Title: A Phase II study of the selective BRAF kinase inhibitor GSK2118436 in subjects with advanced non-small cell lung cancer and BRAF mutations
Phase: II Disease Site: Lung
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this research study is to test the safety of the drug GSK2118436 (dabrafenib)
and how well it works and what effects, good or bad, it has on people with non-small cell
lung cancer whose tumors have genetic change called a BRAF mutation.
 
More Information:
ClinicalTrials.Gov Link
Internal Protocol Documents (requires Siteman administrative database password)